tafamidis meglumine
Drug ingredientThis chemical is an active pharmaceutical ingredient used in FDA-regulated drugs.
Where It Comes From
13 FDA-registered drug labelers
Alivus Life Sciences Limited
Apothecon Pharmaceuticals Pvt Ltd
Aurobindo Pharma Limited
Biophore india pharmaceutical PVT Ltd
Catalent Pharma Solutions, LLC
DELMAR CHEMICALS INC
Honour Lab Limited
Inke SA
MSN Laboratories Private Limited
Neuland Laboratories Limited
NURAY CHEMICALS PRIVATE LIMITED
Pfizer Laboratories Div Pfizer Inc
TAPI Croatia Industries Ltd.
Why It Matters
Sectors
Health
Downstream Uses
Appears in 1 drug and cosmetic product listings (FDA).
- •Vyndaqel
FDA Shortage Status
Whether any manufacturer currently reports this drug as in shortage on the FDA Drug Shortages database. "Active Shortage" means at least one presentation has status "current."
No Shortage
Shortage History
Each row is a separate manufacturer's FDA shortage filing — not a timeline for the drug as a whole. Multiple "current" entries are normal: each manufacturer/NDC files independently. Status reflects the manufacturer's report; reason describes their supply situation (Available, Unavailable, or to be discontinued).
to be discontinued
Tafamidis Meglumine Capsule
09/29/2025Chemical Identity
CAS951395-08-7
PubChem CID24970412
DTXSIDDTXSID50915094
FormulaC21H24Cl2N2O8
Mol. Weight503.3 g/mol
SMILESCNCC(C(C(C(CO)O)O)O)O.C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl
Data Sources
249704122026-04-07
https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/tafamidis meglumine/cids/JSON
Archive: data/sources/pubchem_name/tafamidis meglumine.json
CAS 951395-08-72026-04-25
https://open.fda.gov/data/ndc/
Archive: data/sources/fda/ndc/ndc.json
CAS 951395-08-72026-06-13
https://api.fda.gov/drug/shortages.json
Archive: data/sources/fda/shortages/shortages.json